Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension: Results From the Randomized, Placebo-Controlled SACRA Study

Circulation

Volumn 139, Issue 18, 2019, Pages 2089-2097

  Kario, Kazuomi ^a   Okada, Kenta ^a   Kato, Mitsutoshi ^a,b   Nishizawa, Masafumi ^a,c   Yoshida, Tetsuro ^a,d   Asano, Tsuguyoshi ^e   Uchiyama, Kazuaki ^f   Niijima, Yawara ^g   Katsuya, Tomohiro ^h,i   Urata, Hidenori ^j   Osuga, Jun Ichi ^k   Fujiwara, Takeshi ^a,l   Yamazaki, Shoji ^a   Tomitani, Naoko ^a   Kanegae, Hiroshi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Sato Clinic of Internal Medicine   (Japan)

^c Minamisanriku Hospital   (Japan)

^d Department of Surgery Onga Nakama Medical Association Onga Hospital   (Japan)

^e Kanamachi Yoshida Clinic   (Japan)

^f Uchiyama Clinic   (Japan)

^g Kan etsu Chuo Hospital   (Japan)

^h Katsuya Clinic   (Japan)

ⁱ OSAKA UNIVERSITY   (Japan)

^j FUKUOKA UNIVERSITY   (Japan)

^k Kawachi gun   (Japan)

^l Higashi Agatsuma Machi National Health Insurance Clinic   (Japan)

more..

Author keywords

hypertension; natriuretic peptides; sodium glucose transporter 2 inhibitors; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; EMPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; METFORMIN; URIC ACID;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BODY MASS; BODY WEIGHT; CLINICAL OUTCOME; CONSTIPATION; CONTROLLED STUDY; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FATIGUE; FEMALE; FOLLOW UP; GENITAL PRURITUS; HOME MONITORING; HUMAN; HYPERTENSION; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; POLYURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THIRST; TREATMENT DURATION; UNCONTROLLED NOCTURNAL HYPERTENSION; URIC ACID BLOOD LEVEL;

EID: 85073678741     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.118.037076     Document Type: Article

References (36)

1. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, Bakker RA, Mark M, Klein T, Eickelmann P. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012; 14: 83-90. doi: 10.1111/j.1463-1326.2011.01517.x
2. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ; EMPA-REG MET Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014; 37: 1650-1659. doi: 10.2337/dc13-2105
3. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, Broedl UC; EMPA-REG METSU Trial Investigators. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013; 36: 3396-3404. doi: 10.2337/dc12-2673
4. Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG PIO™ trial investigators. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014; 16: 147-158. doi: 10.1111/dom.12188
5. Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, Broedl UC; EMPA-REG MONO trial investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013; 1: 208-219. doi: 10.1016/S2213-8587(13)70084-6
6. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016; 37: 1526-1534. doi: 10.1093/eurheartj/ehv728
7. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375: 323-334. doi: 10.1056/NEJMoa1515920
8. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117-2128. doi: 10.1056/NEJMoa1504720
9. Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Björklund-Bodegård K, Richart T, Ohkubo T, Kuznetsova T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Wang J, Sandoya E, O'Brien E, Staessen JA; International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) investigators. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007; 370: 1219-1229. doi: 10.1016/S0140-6736(07)61538-4
10. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. Hypertension. 2011; 57: 3-10. doi: 10.1161/HYPERTENSIONAHA.109.133900
11. Ingelsson E, Björklund-Bodegård K, Lind L, Arnlöv J, Sundström J. Diurnal blood pressure pattern and risk of congestive heart failure. JAMA. 2006; 295: 2859-2866. doi: 10.1001/jama.295.24.2859
12. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-Analysis of 102 prospective studies. Lancet. 2010; 375: 2215-2222. doi: 10.1016/S0140-6736(10)60484-9
13. Astrup AS, Nielsen FS, Rossing P, Ali S, Kastrup J, Smidt UM, Parving HH. Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study. J Hypertens. 2007; 25: 2479-2485. doi: 10.1097/HJH.0b013e3282f06428
14. Bouhanick B, Bongard V, Amar J, Bousquel S, Chamontin B. Prognostic value of nocturnal blood pressure and reverse-dipping status on the occurrence of cardiovascular events in hypertensive diabetic patients. Diabetes Metab. 2008; 34(6 pt 1): 560-567. doi: 10.1016/j. diabet.2008.05.005
15. Wijkman M, Länne T, Engvall J, Lindström T, Ostgren CJ, Nystrom FH. Masked nocturnal hypertension-A novel marker of risk in type 2 diabetes. Diabetologia. 2009; 52: 1258-1264. doi: 10.1007/s00125-009-1369-9
16. Mizuno H, Hoshide S, Fukutomi M, Kario K. Differing effects of aliskiren/amlodipine combination and high-dose amlodipine monotherapy on ambulatory blood pressure and target organ protection. J Clin Hypertens (Greenwich). 2016; 18: 70-78. doi: 10.1111/jch.12618
17. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53: 982-992. doi: 10.1053/j.ajkd.2008.12.034
18. Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ; EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015; 38: 420-428. doi: 10.2337/dc14-1096
19. Hermida RC, Ayala DE, Mojón A, Fernández JR. Sleep-Time blood pressure as a therapeutic target for cardiovascular risk reduction in type 2 diabetes. Am J Hypertens. 2012; 25: 325-334. doi: 10.1038/ajh.2011.231
20. Kario K. Evidence and perspectives on the 24-hour management of hypertension: hemodynamic biomarker-initiated 'anticipation medicine' for zero cardiovascular event. Prog Cardiovasc Dis. 2016; 59: 262-281. doi: 10.1016/j.pcad.2016.04.001
21. Kario K, Saito I, Kushiro T, Teramukai S, Ishikawa Y, Mori Y, Kobayashi F, Shimada K. Home blood pressure and cardiovascular outcomes in patients during antihypertensive therapy: primary results of HONEST, a large-scale prospective, real-world observational study. Hypertension. 2014; 64: 989-996. doi: 10.1161/HYPERTENSIONAHA.114.04262
22. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-Analysis. Lancet. 2016; 387: 957-967. doi: 10.1016/S0140-6736(15)01225-8
23. Hoshide S, Kario K, de la Sierra A, Bilo G, Schillaci G, Banegas JR, Gorostidi M, Segura J, Lombardi C, Omboni S, Ruilope L, Mancia G, Parati G. Ethnic differences in the degree of morning blood pressure surge and in its determinants between Japanese and European hypertensive subjects: data from the ARTEMIS study. Hypertension. 2015; 66: 750-756. doi: 10.1161/HYPERTENSIONAHA.115.05958
24. Kario K, Bhatt DL, Brar S, Bakris GL. Differences in dynamic blood pressure variability between Japanese and American treatment-resistant hypertensive populations. Circ J. 2017; 81: 948-957. doi: 10.1253/circj. CJ-16-1237
25. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003; 107: 1401-1406. doi: 10.1161/01.CIR.0000056521.67546.AA
26. Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, Broedl UC, Johansen OE. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension. 2016; 68: 1355-1364. doi: 10.1161/HYPERTENSIONAHA.116.07703
27. Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, Carbone S, Abbate A, Dixon DL. Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-Analysis. J Am Heart Assoc. 2017; 6: e005686. doi: 10.1161/JAHA.117.005686
28. Katsuya T, Ishikawa K, Sugimoto K, Rakugi H, Ogihara T. Salt sensitivity of Japanese from the viewpoint of gene polymorphism. Hypertens Res. 2003; 26: 521-525. doi: 10.1291/hypres.26.521
29. Powles J, Fahimi S, Micha R, Khatibzadeh S, Shi P, Ezzati M, Engell RE, Lim SS, Danaei G, Mozaffarian D. Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open. 2013; 3: e003733. doi: 10.1136/bmjopen-2013-003733
30. Kaku K, Lee J, Mattheus M, Kaspers S, George J, Woerle HJ; EMPA-REG OUTCOME® Investigators. Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from EMPA-REG OUTCOME®. Circ J. 2017; 81: 227-234. doi: 10.1253/circj.CJ-16-1148
31. Majewski C, Bakris GL. Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015; 38: 429-430. doi: 10.2337/dc14-1596
32. Karg MV, Bosch A, Kannenkeril D, Striepe K, Ott C, Schneider MP, Boemke-Zelch F, Linz P, Nagel AM, Titze J, Uder M, Schmieder RE. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovasc Diabetol. 2018; 17: 5. doi: 10.1186/s12933-017-0654-z
33. Kawasoe S, Maruguchi Y, Kajiya S, Uenomachi H, Miyata M, Kawasoe M, Kubozono T, Ohishi M. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. BMC Pharmacol Toxicol. 2017; 18: 23. doi: 10.1186/s40360-017-0125-x
34. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004; 350: 655-663. doi: 10.1056/NEJMoa031994
35. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016; 134: 752-772. doi: 10.1161/CIRCULATIONAHA. 116.021887
36. Lytvyn Y, Škrtic M, Yang GK, Yip PM, Perkins BA, Cherney DZ. Glycosuriamediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2015; 308: F77-F83. doi: 10.1152/ajprenal.00555.2014